Conflicting to the repeatedly held misinterpretations, bone is a comparatively active organ that experience notable changes as contrast to other organs in the body. Bone metabolism is related with diseases impacting bone and mineral metabolism that includes a wide range of skeletal and soft tissue infection. In general, these infections may be combined as Paget disease of bone, osteoporosis, developmental disorders of bone and hyperparathyroidism. Geriatric population that is nearby 28 million in America get influenced by osteoporosis, and the fetch to treat for osteoporosis-associated fractures was evaluated to be about $14.8 billion every year a short time before. Other metabolic bone diseases are comparatively lacking, but anyhow are a source of notable cost to society and morbidity. Bone is a specific tissue intended to deliver enough potency to resist involuntary forces, but still to be light enough to permit flexibility. It has a complicated composition and experience constant remodeling or metabolism. To treat bone metabolism diseases there are several tests available in market and cost for treatment is much higher as most of the population in the world is threatened by bone metabolism diseases the market will drive towards growth for bone metabolism tests.
On the basis of test types global bone metabolism test market is segmented into:
Bone marker test
C-telopeptide marker test
P1NP marker test
N-telopeptide marker test
On the basis of application types global bone metabolism test market is segmented into:
On the basis of end users global bone metabolism test market is segmented into:
On the basis of test types global bone metabolism test market can be segmented into bone marker test and immunoassay where, bone markers are related with biochemical marker that specify breakdown of bone that can be used to estimate individual’s bone fracture risk at the moment when density of mineral measurement does not specify the results and immunoassay is related with a laboratory technique that recognize and evaluate a protein like hormone or enzyme based on capacity to act as an antibody or antigen in chemical reaction. Furthermore, Bone marker tests are categorized into C-Telopeptide marker test, P1NP marker test, N- telopeptide marker test and osteocalcin test. C-Telopeptide marker test used to monitor anti-restoratives therapies like hormone replacement therapy in people with low bone mass and in women with menopause and is peptide fragment from the carboxyl terminal end of the protein matrix. P1NP Marker is for bone formation occurred from osteoblast and it is recommended that the test should be performed before the treatment of osteoporosis and again after 3 to 6 months. N-telopeptide is a peptide fragment used to monitor another marker therapy from amino terminal end of the protein matrix and osteocalcin is form of protein formed by osteoblast this test may be simulated by using drug warfarin. Moreover, Immunoassay is categorized into ELISA and RIA where enzyme-linked immunosorbent assay (ELISA) is used to detect the presence of antibody and antigen through a biochemical mechanism and radioimmunoassay (RIA) is in-vitro assay technique to detect antigen in the body with the help of antibody present in the body.
On the basis of application types global bone metabolism test market is segmented into hyperparathyroidism, hypoparathyroidism, osteoporosis, Paget’s disease and kidney disease. Hyperparathyroidism mostly occur in people having age more than 50 while neonatal or new born babies are highly threatened by hypoparathyroidism. Osteoporosis has dominated the market in bone metabolism diseases and is the most common disease occurring in women on in tenth will have osteoporosis at the age of 60, more than 8.9 million fractures are recorded yearly due to osteoporosis throughout the world. Rising penetrance rate of osteoporosis is driving the bone metabolism test market towards the growth in the forecast period. Paget’s disease is most common in men than women in that bone growth is too large and weak.
On the basis of geography, global bone metabolism test market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and Middle East Africa. North America and Latin America are the dominating market in global bone metabolism test market followed by Europe as penetrance of osteoporosis, hyperparathyroidism is increasing in large amount. Asia pacific and Middle East Africa is rising market for bone metabolism test market as volume has increased in last few years. Hence, companies are making strategies to enter in the market.
Some of the major players in global metabolism test market are: Siemens Healthcare GmbH, F. Hoffmann-La Roche, Abbott GmbH & Co. KG, DiaSorin, bioMerieux SA and Quidel Corporation. Siemens Healthcare GmbH Has largest market share in bone metabolism test market. The increasing competition in key players to develop new therapy and technology for bone metabolism test will drive the market globally.
The report covers exhaustive analysis on:
Bone Metabolism Test Market Segments
Bone Metabolism Test Market Dynamics
Historical Actual Market Size, 2013 - 2015
Bone Metabolism Test Market Size & Forecast 2017 to 2027
Bone Metabolism Test Market Current Trends/Issues/Challenges
Competition & Companies involved
Bone Metabolism Test Market Drivers and Restraints
Regional analysis includes
Middle East & Africa
Detailed overview of parent market
Changing market dynamics of the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance
Must-have information for market players to sustain and enhance their market footprint
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.